Effective March 1, 2017, C. Ronald Kahn, M.D., joined The FASEB Journal's prestigious roster of associate editors (AE). In this role he manages the peer review and submission decision processes, and will collaborate with journal’s current group of AEs, including Helen Blau, Ph.D., Stanford University; Robert Goldman, Ph.D., Northwestern University; Laura Goldsmith, Ph.D., Rutgers New Jersey Medical School; Robert Haselkorn, Ph.D., University of Chicago; Charles N. Serhan, Ph.D., D.Sc., Brigham and Women's Hospital, Harvard Institutes of Medicine; and Babette Weksler, Weill Cornell Medical College; Richard D. Ye, Ph.D., University of Macau; as well as editor-in-chief, Thoru Pederson, Ph.D., University of Massachusetts Medical School. Biographical sketches for each editor can be found on The FASEB Journal's website.
“I am very excited to be a part of this great team,” said Kahn regarding his new appointment as associate editor to The FASEB Journal. “The high quality and broad nature of The FASEB Journal puts it in a special place in the field.”
C. Ronald Kahn is a world-recognized expert in diabetes/obesity research and a preeminent investigator of insulin signal transduction and mechanisms of altered signaling in metabolic disease. He currently serves as the Chief Academic Officer, Head of the Section on Integrative Physiology and Metabolism at Joslin Diabetes Center and the Mary K. Iacocca Professor of Medicine at Harvard Medical School. Prior to this position, Kahn served as Research Director of the Joslin Diabetes Center from 1981 to 2000, and President of Joslin from 2001 to 2007. Dr. Kahn holds undergraduate and medical degrees from the University of Louisville and has honorary doctorates from the University of Paris, University of Louisville, University of Geneva, University of Copenhagen, Louisiana State University, and Washington University in St. Louis, and is an honorary Professor and Director of the Diabetes Center at Peking University School of Medicine. Over the course of his career, he has received more than 70 awards and honors. For more biographical information, visit the journal website.
“Despite major advances in recent decades, diabetes and its syndromic comorbidity remain a major frontier in biomedical science,” said Pederson. “Having an investigator of Dr. Kahn’s experience and stature join The FASEB Journal’s Associate Editors will enable us to increase our coverage of the diabetes field, both as basic and translational research. We are delighted to have him with us.”
Submit to The FASEB Journal by visiting the journal submission website, and sign up here to receive monthly highlights. The FASEB Journal is published by the Federation of the American Societies for Experimental Biology (FASEB). It is the world's most cited biology journal according to the Institute for Scientific Information and has been recognized by the Special Libraries Association as one of the top 100 most influential biomedical journals of the past century.